Search Within

Genitourinary Oncology Service

Formats
  1. Journal Article (2795)
  2. Meeting Abstract (2526)
  3. Review (121)
  4. Book Section (83)
  5. Editorial (57)
  6. Correspondence (34)
  7. Conference Paper (29)
  8. Guidelines (25)
  9. Research Letter (18)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Solid Tumor Oncology Division (5696)
  2. Department of Medicine (5686)
  3. GSK Faculty (1659)
  4. Human Oncology and Pathogenesis Program (1158)
  5. Department of Pathology and Laboratory Medicine (1130)
  6. Surgery (1021)

More Groups

People
  1. Robert Motzer (1252)
  2. Howard Scher (1133)
  3. David Solit (786)
  4. Dean Bajorin (664)
  5. Michael Morris (588)
  6. Jonathan Rosenberg (525)

More People

Years
  1. 2025 (204)
  2. 2024 (294)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1713)
  2. Annals of Oncology (304)
  3. Clinical Cancer Research (283)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (123)

More Publications

Publishers
  1. American Society of Clinical Oncology (1780)
  2. American Association for Cancer Research (690)
  3. Oxford University Press (414)
  4. Elsevier Science, Inc. (396)
  5. Elsevier Inc. (380)
  6. Nature Publishing Group (304)

More Publishers

Results (5696)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Datasets for the reporting of neoplasia of the testis: Recommendations from the International Collaboration on Cancer Reporting
    Review

    Berney, D. M.; Comperat, E.; Feldman, D. R.; Hamilton, R. J.; Idrees, M. T.; Samaratunga, H.; Tickoo, S. K.; Yilmaz, A.; Srigley, J. R.
    Histopathology (2019)

    Fulltext@MSK | Save
  • Survivorship care
    Book Section

    Tonorezos, E.; Baxi, S. S.; Blinder, V.; Feldman, D. R.; Friedman, D. N.; Matasar, M.; Salz, T.; Shahrokni, A.; Oeffinger, K. C.
    In The American Cancer Society (Eds.) The American Cancer Society's Principles of Oncology: Prevention to Survivorship (2018)

    Fulltext@MSK | Save
  • Refining actionable HER2 alterations in lung cancers through next generation sequencing (NGS)
    Meeting Abstract

    Xu, C.; Myers, M.; Buonocore, D. J.; Razavi, P.; Shen, R.; Lai, W. C. V.; Smyth, L. M.; Zheng, T.; Ni, A.; Solit, D. B.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Treatment outcomes of cutaneous adverse events to immune checkpoint inhibitors
    Meeting Abstract

    Wu, J.; Freites-Martinez, A.; Hellmann, M. D.; Rosenberg, J. E.; Motzer, R. J.; Chapman, P. B.; Rizvi, N. A.; Geskin, L. J.; Reed, V. A.; Dusza, S. W.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • First-line PD-1/PD-L1 inhibitor followed by carboplatin (carbo)-based chemotherapy (chemo) or the reverse sequence in cisplatin-ineligible metastatic urothelial cancer (mUC) patients (pts)
    Meeting Abstract

    Wei, X. X.; Lundgren, K.; Teo, M. Y.; Rosenberg, J. E.; Koshkin, V. S.; Grivas, P.; Carril, L.; Castellano, D. E.; Velho, P.; Hahn, N. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC)
    Meeting Abstract

    Voss, M. H.; Novik, J. B.; Hellmann, M. D.; Ball, M.; Hakimi, A. A.; Miao, D.; Margolis, C.; Horak, C.; Wind-Rotolo, M.; De Velasco, G.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Characterizing tumor immune microenvironment (TME) and outcomes for 409 patients (pts) treated on COMPARZ: Distinct clusters emphasize immune infiltration vs. angiogenesis
    Meeting Abstract

    Voss, M. H.; Kuo, F.; Sanchez, A.; Ostrovnaya, I.; Cheng, Y.; Patel, P.; Marker, M.; Reising, A.; Chan, T. A. T.; Motzer, R. J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)
    Meeting Abstract

    Vuky, J.; Balar, A. V.; Castellano, D. E.; O'Donnell, P. H.; Grivas, P.; Bellmunt, J.; Powles, T.; Bajorin, D. F.; Hahn, N. M.; De Wit, R.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Impact of SLCO1B3 single nucleotide polymorphisms (SNPs) on outcomes in patients with castration resistant prostate cancer (CRPC) treated with docetaxel
    Meeting Abstract

    Tripathi, A.; Xie, W.; Sweeney, C.; Choudhury, A. D.; Pomerantz, M.; Wei, X. X.; Taplin, M. E.; Choueiri, T. K.; Lee, G. S. M.; Kantoff, P. W.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC)
    Meeting Abstract

    Tannir, N. M.; Naing, A.; Infante, J. R.; Papadopoulos, K. P.; Wong, D. J. L.; Korn, M.; Aljumaily, R.; Autio, K. A.; Pant, S.; Bauer, T. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save